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1078–5884/00Inhibition of In-stent Restenosis in Rabbit Iliac Arteries
with Photodynamic Therapy
M. Pai,1 W. Jamal,1 A. Mosse,1 C. Bishop,2 S. Bown1 and J. McEwan1*1The Royal Free and University College London Medical School, and 2The University College London
Hospitals NHS Trust, London, UKObjectives. Photodynamic therapy (PDT, the combination of light with a photosensitising drug in the presence of oxygen)
inhibits restenosis after angioplasty without stenting. This study assesses the potential of PDT for prevention of in-stent re-
stenosis.
Design and methods. Normal rabbits were given the photosensitising agent 5-aminolaevulinic acid (ALA) 60 mg/kg, 3 h
prior to endovascular illumination of the iliac artery (635 nm at 50 J/cm2) either immediately before or after deployment of
an oversized (3 mm diameter) stent. PDT treated arteries were retrieved 3 or 28 days later and assessed for cell counts and
vascular morphometry. Control arteries (stent but no PDT) were examined at 28 days.
Results. There were no adverse events and all vessels were patent at the end of the study. At 3 days there was almost
complete medial cell ablation when light was delivered before stent deployment (17G1 cells/hpf), with little effect when
illumination followed stent deployment (184G17 cells/hpf, p!0.0001). Twenty-eight days after PDT, the neointimal areas
were 1.41G0.52 mm2 (stent with no PDT), 1.24G0.54 mm2 (light after stent) and 0.60G0.21 mm2 (light before stent)
(pZ0.004).
Conclusions. PDT before stent deployment caused almost complete medial cell ablation at 3 days with inhibition of in-stent
restenosis at 28 days. PDT is worthy of further study as an adjuvant to percutaneous intervention in patients with vascular
disease.Keywords: In-stent restenosis; Photodynamic therapy.Introduction
Vascular smooth muscle cell (VSMC) proliferation
with migration into the intima is a major contributor to
the development of restenosis after angioplasty or
stent deployment. No systemic pharmacological agent
has yet been shown to resolve this problem. Most
current interest centres on techniques that alter cell
proliferation, either by elution of a cytotoxic drug from
the stent wall or by brachytherapy.1 An alternative
approach to regulation of VSMC proliferation is
photodynamic therapy (PDT). PDT produces local
cell killing with low power red light after the prior
administration of a photosensitising drug and in the
presence of oxygen.2
Several photosensitising agents have been studied
in relation to arterial disease, particularly motexafinng author. Jean R. McEwan, BSc, MB ChB, PhD, FRCP,
Consultant Cardiologist, Cardiovascular Repair and
Group, Centre for Cardiovascular Biology and
F Laboratories at University College London, The
te, 5 University Street, London WC1E 6JJ, UK.
: j.mcewan@ucl.ac.uk
0573 + 09 $35.00/0 q 2005 Elsevier Ltd. All rights reserlutetium and 5-amino-laevulinic acid (ALA, which is
converted in vivo into the photoactive derivative,
protoporphyrin IX, as part of the chemical chain for
the synthesis of haem). PDT experiments on normal
arteries have demonstrated endothelial denudation,
which heals in a few days, and medial cell depletion,
which recovers over a much longer period, but with
maintenance of the vessel integrity and strength at all
times after treatment. There has been no evidence of
aneurysm formation or thrombosis.3–5 Further studies
have shown that PDT can inhibit neointimal hyper-
plasia following angioplasty to rat carotid, rabbit iliac
and pig coronary arteries.6–9 Pilot safety studies of its
application to peripheral and coronary disease in man
have now been reported.10–13
About 80% of coronary angioplasties are now
stented. These vessels may re-occlude by neointimal
hyperplasia brought about by a number of different
processes including VSMC proliferation, causing in-
stent restenosis.14,15 The combination of PDT and
arterial stenting has not yet been studied in detail.
The aim of the present study was to address thisEur J Vasc Endovasc Surg 30, 573–581 (2005)
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affects neointimal hyperplasia when given before or
after stenting rabbit iliac arteries.MethodsPhotosensitiser
The photosensitising agent used was 5-aminola-
evulinic acid (ALA, supplied as the hydrochloride,
DUSA Pharmaceuticals, USA). This was dissolved in
normal saline and buffered to pH 7 with sodium
bicarbonate. This was administered intravenously at a
dose of 60 mg/kg 3 h before light delivery.3Animals and surgical techniques
New-Zealand white rabbits (nZ32, 2.5–3 kg) were
used in this study. The rabbits were anaesthetised
using Hypnorm (fentanyl/fluanisone) 0.5 ml/kg
(Janssen), and Hypnovel (midazolam) 0.05 ml/kg
(Roche) for induction and maintained with inhalation
anaesthesia using halothane. Following skin prepar-
ation, the superficial femoral artery was exposed and
bathed externally in papaverine (Martindale, Romford)
for 2 min. An arteriotomy allowed insertion of a 2F
canula and an angiogram delineated the anatomy of
the aorta and the iliacs. Images were obtained using a
C arm image intensifier with a road mapping facility
(Siemens S2000, Erlangen, Germany), which allowed
accurate intravascular positioning and recorded on
super VHS video tape. At the end of stent and light
delivery the superficial femoral artery was ligated and
the wound repaired. The rabbits were recovered and
maintained on standard rabbit chow and daily aspirin
(20 mg/kg). All animals were treated in accordance
with the Animals (Scientific Procedures) Act 1986
under project and personal licences approved by the
Home Office (UK Government). The investigation
conforms with the ‘Guide for the Care and Use of
Laboratory Animals’ by the US National Institute of
Health (NIH Publicaton No. 85-23, revised 1996).Stenting and light delivery
A specially constructed transparent balloon catheter
was used for endovascular illumination. (Occam, The
Netherlands). This had a 20 mm by 3 mm balloon with
a blind ending channel into which was pre-loaded an
optical fibre (0.2 mm core and a 20 mm distal radial
light diffuser of diameter 0.5 mm), with radio opaqueEur J Vasc Endovasc Surg Vol 30, 12 2005markers. The catheter was introduced over a monorail
guide wire into the ipsi-lateral common iliac artery so
that the balloon lay in the target segment just proximal
to the iliac bifurcation. The wire was pulled back from
the balloon when the correct position was obtained.
During light delivery the balloon was inflated with air
sufficiently to occlude the blood flow but not to
overstretch the vessel. Red light was delivered from
a diode laser (Diomed, Cambridge UK) at 635 nm,
80–100 mW/cm of diffuser with a total dose of
50 J/cm2 on the surface of the balloon. The total light
delivery time in each procedure was 5–600 s, exclud-
ing a 60 s pause after 1 min of light delivery. Such a
pause during illumination has previously been shown
to increase the efficacy of PDT with ALA16,17 After
light delivery the deflated balloon, guide wire and
optical fibre were removed. Either before or after light
delivery, a 15 mm by 3 mm stent was loaded on a
3 mm balloon catheter, introduced through the
femoral arteriotomy, positioned under X-ray guidance
and deployed at the target site at 10 atm. pressure.
Animals were randomly assigned to one of three
groups:
Group 1: (nZ8): Stent deployed without drug or
light application.
Group 2: (nZ12): ALA given 3 h before surgery
with light delivery for PDT after stent deployment.
Group 3: (nZ12): ALA given 3 h before surgery with
light delivery for PDT before stent deployment.Tissue harvesting and processing
All rabbits were killed by administration of an overdose
of 20% phenobarbiturate. The abdomen was opened, the
retroperitoneum exposed, and the aorta isolated and
tied above its bifurcation. An 18F IV canula was
introduced into the distal aorta and the distal vessels
were pressure perfused at 100 mmHg with 4% formalin
for 10 min. The iliac arteries were then isolated and
removed and fixed for a further 16 h in 4% formalin.
Four rabbits in groups 2 and 3 were culled at 3 days.
In these animals the stented vessels were isolated, cut
open along the longitudinal axis and peeled from the
stent. The untreated contra lateral iliac arteries were
used as controls. The harvested tissues were
embedded in paraffin wax, cut into 4 mm sections
and stained with haematoxylin and eosin (H & E).
Photomicrographs of these sections were taken (JVC
TK-1281) and transferred onto a personal computer for
morphometric analysis using the Lucia-M (version
3.52a) programme. Three sections from each vessel
Fig. 1. Vascular smooth muscle cell (VSMC) counts in group 2 and 3 at 3 and 28 days after PDTcompared to cell counts in the
normal rabbit artery media showing significant ablation in group 3 at 3 days. (p!0.005 group 2 vs. group3) there is partial
repopulation of the media in group 3 at 28 days.
PDT in In-stent Restenosis 575were examined. On each, the condition of the endo-
thelium was documented and the number of VSMC
nuclei per high power field (20!objective) was
counted in 10 fields in all quadrants to calculate a
mean count per high power field.
The other rabbits (eight in each of the three groups)
were culled at 28 days after stenting and light delivery.
These vessels were embedded in LR white resin using
standard techniques with the stent left in situ.18,19
Vessels were cut into 10 mm sections with the stents
in situ on a tungsten microtome and stained subse-
quently with H & E.
Morphometric analysis included measurement of
the luminal area, the area within the internal elastic
lamina (IEL), the area within the external elastic
lamina (EEL), and the intimal thickness. The intimal
area was calculated by subtracting the luminal area
from the area within the IEL. Similarly the medial
area was calculated by subtracting the area within
the IEL from the area within the EEL. The best
section, i.e. one that was intact and whole, from each
vessel was used for measurement. Intimal thickness
was measured at 10 different points around the
artery circumference, at approximately equal separ-
ations. The mean of these 10 measurements was
used in the subsequent analysis.Statistical analysis
All values were expressed as meanGSD. Statistical
analysis was by the comparison of the means from each
group using the unpaired Student t-test. Inter and intra-
observer variability was assessed by reanalysis of a
representative sample of histological sections. Area and
thickness calculations were made by one observer on
two separate occasions and by a second independent
observer on one occasion. There was no significant
difference in the inter and intra-observer readings. A p
value of !0.05 was considered significant.Results
All animals survived to the end of the experimental
period and there was no evidence of thrombosis,
rupture or aneurysm formation in either of the PDT
treatment groups or in the control group.
The media cell counts 3 days and 28 days after
stenting and light delivery are shown in Fig. 1. Light
treatment before stenting significantly reduced VSMC
in the media at 3 days, whereas light treatment after
stenting did not. (Fig. 2(a) and (b)). In neither group
were endothelial-like cells seen on the luminal surfaceEur J Vasc Endovasc Surg Vol 30, 12 2005
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Table 1. Morphometric measurements at 28 days after PDT in all groups
Stent only controls
(group 1)
Light delivery after stenting
(group 2)
Light delivery before stenting
(group 3)
Area within EEL(mm2) 5.47G1.05 5.81G1.33 5.76G1.32
Area within IEL (mm2) 5.05G0.92 5.28G1.15 5.30G1.25
Luminal area (mm2) 3.64G0.40 4.04G0.67 4.71G1.07*
Intimal area (mm2) 1.41G0.52 1.24G0.54 0.60G0.21†
Intimal thickness (mm) 0.90G0.36 0.88G0.29 0.47G0.13†
Medial area (mm2) 0.42G0.15 0.53G0.33 0.46G0.24
* Statistically significant compared to group 1 (p!0.05).
† Statistically significant compared to group 1 and 2 (p!0.007).
PDT in In-stent Restenosis 577of the retrieved arterial fragments from which the stent
had been removed prior to processing. Observations
of the sections of the resin-embedded stented arteries
at 28 days showed that there was partial repopulation
of the media in group 3 while the other two groups
retained their cellularity throughout. (56G7 counts per
high power field in group 3, 155G14 in group 2 and
167G13 in group 1). Representative samples are
shown in Fig. 2(c)–(f).
The morphometric measurements 28 days after
stenting are shown in Table 1. By this time, the stented
arteries had all developed a neointimal layer, but in
group 3 (PDT light before stent deployment), this was
significantly thinner than in the other two groups.
There was no statistical difference in either the area
within the EEL or the area within the IEL confirming
that deployment of the stents was to a similar diameter
in all groups with no expansile remodelling in PDT
treated groups. The percentage stenosis was calculated
as the ratio of the neointimal area to the area within the
IEL and was significantly less in group 3 than in either
of the other two groups (Fig. 3).
While no immunohistochemical confirmation of
endothelial integrity was possible with the LR white
resin mounted tissue, a single layer of flat endo-
thelium-like cells lined the stented arteries at 28 days
in all groups (Fig. 2(g) and (h)).Discussion
This study is the first to demonstrate that PDT can be
an effective adjuvant to arterial stenting, significantly
reducing intimal hyperplasia, without detrimentalFig. 2. Photomicrographs of rabbit artery. (a) and (b): Artery pee
embedded. (a) Group 2 (light after stent), showing minimal de
deformity created by the stent strut (H & E!10). (b) Group 3 (lig
10). (c)–(h): Arteries embedded in LR white resin 28 days after
PDT) showing marked neointimal hyperplasia (!10). (d) Grou
(!10). (e) Group 3 (PDT before stent) showing a significa
magnification of (e), showing the uniformity of inhibition of ne
illustrating a contiguous layer of flattened endothelial-like c
illustrating endothelial-like cells (arrows) as in (g) (!20).
3effects on vascular integrity and thrombogenicity.
However, activation of photosensitiser must take
place before rather than after the stent is deployed.
We used the rabbit iliac artery, a well-established
model for in-stent restenosis, although these are
disease-free, elastic arteries. There may be a difference
in response when PDT is applied to atherosclerotic
vessels with the addition of both cellular elements
such as macrophages and fibroblasts and a lipid core.
Previous studies have shown the in vivo accumulation
of photosensitisers in atherosclerotic plaques both in
the cellular and non-cellular elements, although this
has not been reported using ALA.20,21 Nevertheless,
rabbit models of atherosclerosis are quite different
from human atherosclerotic lesions and do not mimic
complex human coronary disease. We considered that
the model we used was appropriate for answering the
key question of how PDT before and after stenting
influenced cell proliferation. Our studies did only
extend to 28 days, but this is a time point frequently
used in preclinical studies.22 Later observations might
have revealed a catch up of the lesion, but we think
this unlikely as our previous studies following PDT
treated arteries in rats for up to 6 months did not show
any marked later cell proliferation.8
In general, the response of tissue to PDT is complex,
with inflammation and microvascular damage, but in
the arterial wall the development of medial apoptotic
bodies, TUNEL staining of residual nuclei and the lack
of an early inflammatory infiltrate suggest that the
predominant effect is apoptosis.23–25 As documented
for PDT as an adjuvant to angioplasty without
stenting, the prevention of intimal hyperplasia and
restenosis seen in this study is linked closely toled from stent 3 days after PDT, fixed in formalin and paraffin
pletion of smooth muscle cells. The arrow head represents a
ht before stent), showing marked cellular depletion (H & E!
stent insertion and cut with the stent in situ. (c) Group 1 (no
p 2 (PDT after stent) showing marked neointimal hyperplasia
nt reduction in neointimal hyperplasia (!10). (f) Lower
ointimal neoplasia. (!4). (g) Group 2 at higher magnification
ells (arrows) lining the stented vessel (!20). (h) Group 3
Eur J Vasc Endovasc Surg Vol 30, 12 2005
Fig. 3. Histogram showing percentage stenosis (ratio of intimal area to area within IEL) in groups 1, 2 and 3 at 28 days.
(p!0.001, group 1 vs. group 3, p!0.002, group 2 vs. group 3).
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the media of pig coronaries illuminated endovascu-
larly,6 consistent with the partial medial cell repopula-
tion at 28 days documented here, although cell
depletion may persist for 6 months or more in rat
carotid arteries.8 In addition to the apoptosis, it has
been suggested that the lack of cell migration after
PDT reflects local PDT-induced cross-linking of matrix
proteins, which renders the interstitium resistant to
proteolytic digestion by migrating cells.26
The striking result from this study is the obser-
vation that the media remained fully populated with
smooth muscle cells with no inhibition of stent-
induced intimal hyperplasia at 28 days if the light
was delivered after stent deployment. There are
several possible explanations. As the ALA was given
at the same time prior to light delivery in both groups
2 and 3, the difference in response is unlikely to be
related to the distribution of protoporphyrin IX (the
photoactive derivative of ALA). PDT requires oxygen.
The simplest explanation is that stent deployment
stretches the arterial wall and makes it hypoxic. It has
been documented previously in the rabbit that
deployment of an oversize stent renders the normal
arterial wall hypoxic. This effect is most marked in the
media. Oxygenation of the endothelial layer is
maintained better from blood flowing through the
lumen of the vessel.27 This may explain why
endothelial loss was seen in arteries illuminated afterEur J Vasc Endovasc Surg Vol 30, 12 2005stent insertion, although this loss may be at least
partially attributable to the trauma of the balloon-
mounted stent delivery. By 28 days all stented arteries
had a layer of endothelial-like cells coating the lumen
surface of the artery. Several studies report complete
and even accelerated regrowth of normal vascular
endothelium after PDT without stenting, with no
evidence of thrombosis or any other impairment of
blood flow.5,28–30 Early re-growth of endothelium after
PDT may play a role in the inhibition of VSMC
proliferation and intimal hyperplasia and may also
play a role in reducing thrombogenic complications
after stent placement.
There are other possible explanations for our
results. The vascular stent is a metal tube mesh, so
optical shadowing from light delivered from within
the lumen of the stent must occur to some degree.
However, the wire of the stent struts is so thin com-
pared with the penetration depth in tissue of the red
light used (typically about 2 mm) that scattering of
light within the tissue should make this a minor
consideration. Nevertheless, a recent report describes
inhibition of intimal hyperplasia from PDT given after
stenting of the femoral artery, but employing illumina-
tion of the external surface of the artery, perhaps
avoiding strut shadowing.31 Another possibility is that
mechanical stretching of the arterial wall by the stent
could lead to on-going stimulation of VSMC prolifer-
ation (in contrast to the single insult of a balloon
PDT in In-stent Restenosis 579angioplasty followed by removal of the balloon).
However, this is less likely as the effect would have
been expected to be the same in both PDT treated
groups.
Most knowledge of the arterial effects of PDT comes
from experiments on arteries in normal animals, but
there are now a few reports of clinical applications.
The first study, reported in 1999, described seven
patients in whom eight lesions had restenosed after
a previous femoral artery angioplasty. All were
asymptomatic with patent vessels 6 months after
repeat angioplasty with adjunctive ALA-PDT.10 A
4 year follow up on the same patients showed that
only one of eight treated sites showed any evidence of
restenosis, despite the absence of any anti-thrombo-
genic treatment other than aspirin.10,12 A randomised
study of femoral angioplasty with and without
adjuvant PDT is currently under way. Motexafin
lutetium has also been tested in clinical trials of
peripheral and coronary vascular disease13 including a
phase 1 study as an adjuvant to stenting in coronary
arteries. The safety and tolerability were excellent and
the late lumen loss and binary restenosis rate were at
least as good as after bare stenting.11 Nevertheless, the
study was not designed to assess the efficacy of
adjuvant PDT, which will require further studies.
The potential value of PDT as an adjunct to balloon
angioplasty compared with other current options such
as the elution of cytotoxic drugs from stents and
brachytherapy, will depend partly on the cost and
convenience of treatment delivery, but more impor-
tantly on the long term biological effects on the arterial
wall. The key role of medial VSMC in the intimal
response to a stent is reflected in the significant
reduction in neointimal area and thickness at 28 days
only under conditions where PDT depletes the VSMC
at 3 days. This correlation is also seen with drug-
eluting stents and brachytherapy.1,32,33
Remodelling with vessel shrinkage is a major
contributor to restenosis after balloon angioplasty.
Previous studies from our group and others have
shown that following angioplasty with adjuvant
endovascular PDT but without stenting, there is
inhibition of constrictive remodelling.34,6 Remodelling
is less important in the presence of a stent, but it is
reassuring that we saw no evidence of aneurysmal
dilatation following PDT, nor signs to suggest stent
mal-apposition, which has been a feature of both
brachytherapy and drug eluting stents.35,36 Further, no
signs of injury to adjacent tissue have been reported
with ALA-PDT, which may reflect the limited tissue
penetration (2 mm) of the 635 nm light used to activate
protoporphyrin IX, the active metabolite of ALA. The
impaired endothelial re-growth after brachytherapyand drug eluting stents has necessitated long term
anti-thrombotic treatment with the associated expense
and risk of bleeding complications.1,37—39 The rapid
re-endothelialisation reported after PDT in animals
allows us to speculate that in the clinical setting
adjuvant PDT may require less subsequent mainten-
ance drug therapy. The endothelium may not heal so
well in atherosclerotic human vessels as it does in non-
atherosclerotic animal arteries, but the one clinical
study so far reported with extended follow up of
4 years, did not describe any evidence of late
thrombotic complications despite only aspirin pro-
phylaxis.12 A recent report on long term follow up of
drug eluting stents described four cases in which drug
eluting stents in coronary arteries thrombosed more
than a year after insertion, when anti-thrombotic
therapy was reduced.40 Two of these patients also
had non drug eluting stents, which did not thrombose.
There were no thrombotic complications in our experi-
ments. On the evidence currently available from this
and other studies, arteries tolerate PDT remarkably
well, in the short and long term, although the clinical
data available is very limited. No reports of arterial
PDT have described any evidence of the chronic changes
known to be associated with ionising radiation.
One of the key attractions of PDT is the nature of the
biological effect. Despite its increasing use in a range of
specialities, there is no evidence of cumulative toxicity
and it has often been used to treat the same site several
times. The photon energy of the red light used is too
low to damage DNA. There is a lack of any effect on
the mechanical integrity of arteries or on the blood
flow through them and a lack of any chronic changes
detectable histologically. This body of evidence makes
PDT an attractive option as a possible alternative to
drug eluting stents and brachytherapy. However, as
PDT has only been shown to work if the light is given
prior to stent deployment, it may not be of value for
the treatment, rather than prophylaxis, of in-stent
restenosis. The published data on stent induced
hypoxia in the wall of arteries showed that there was
some improvement in the hypoxia when the stents had
been in situ for several weeks, but further detailed
experiments would be required to see if PDT can have
any value for treating rather than preventing in-stent
restenosis.
In practical terms, PDT is more complex than
inserting a drug eluting stent, but with the design of
balloon catheter described here, it is straightforward to
deliver the light intraluminally. The need to adminis-
ter ALA several hours prior to angioplasty and to take
simple precautions against exposure to bright ambient
light for 1–2 days are relatively minor inconveniences.Eur J Vasc Endovasc Surg Vol 30, 12 2005
M. Pai et al.580The safety precautions required are certainly less than
are needed for brachytherapy.
On the limited evidence available to date, it would
appear that PDT may be able to reduce the incidence of
re-stenosis after angioplasty, with or without stenting,
with few, if any, long term adverse effects on the
arterial wall. Further studies are needed to clarify the
mechanisms involved, particularly in stented arteries,
and to undertake larger scale clinical trials.Acknowledgements
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